Tyvaso Crossword Puzzle

Edit Answers
123456789101112131415161718192021222324252627282930
Across
  1. 2. Opened blister strips must be used within _____ days
  2. 3. Initial mcg dose of Tyvaso DPI
  3. 7. Initially approved in 2002
  4. 9. The most frequent adverse event that occurs with Tyvaso
  5. 11. The percentage of the overall reduction in the risk of a clinical worsening event with the use of Tyvaso in the INCREASE trial
  6. 12. Administer using a single inhalation per cartridge
  7. 13. The test subjects used to prove there was no evidence for carcinogenic potential associated with Treprostinil use
  8. 15. Institutional kits contain _____ blister strips
  9. 17. Patients on Tyvaso had a change from baseline in peak 6MWD of ________ meters at Week 12 in the TRIUMPH study
  10. 19. The study that demonstrated Tyvaso could be safely used in WHO Group 3 patients.
  11. 20. The safety and effectiveness of Tyvaso has not been established in this patient population
  12. 24. Where can I find the most updated version of the PI for Tyvaso?
  13. 25. The study that put Tyvaso DPI on the map
  14. 26. Do not ______ the Tyvaso DPI inhaler
  15. 27. The number of mcg delivered in a single breath of Tyvaso
  16. 28. Rifampin _______ exposure to Treprostinil
  17. 29. Patients were on this background therapy in the clinical trial for Tyvaso
  18. 30. Patients were on this background therapy in the clinical trial for Tyvaso
Down
  1. 1. Tyvaso may cause acute_______
  2. 4. Treprostinil is substantially metabolized by the _______
  3. 5. Once the foil pack is opened, the ampules should be used within ______ days.
  4. 6. Tyvaso should be continued at the _______ tolerated dose
  5. 8. In ______ studies, no adverse reproductive and developmental effects were seen for Treprostinil
  6. 10. The Tyvaso Inhalation System is an ________, pulsed delivery device
  7. 11. The study that put Tyvaso on the map
  8. 14. Indicated for WHO Group 1 and 3
  9. 16. Treprostinil is not cleared by _________
  10. 18. If refrigerated, cartridges and inhalers should be at room temperature for _____ minutes before use
  11. 21. Tyvaso may cause symptomatic _________
  12. 22. Treprostinil does not affect the pharmacokinetics or pharmacodynamics of this medication
  13. 23. An example of a CYP2C8 inhibitor